GENE TECHNOLOGY FORUM 2001

VANEMUINE CONCERT HALL

Download final programme (pdf) Download abstracts (pdf) Thursday, Sept 13, 2001
18:00-18:45	Registration at the Vanemuine Concert Hall
18:45-19:00	OPENING of the FORUM Prof. Peeter Tulviste, Chairman of the Tartu City Council Former Rector Magnificus of The University of Tartu, Estonia
19:00-20:00 Keynote	OPENING SESSION Prof. Klaus Lindpaintner Vice President and Director, Roche Genetics, F. Hoffmann-La Roche AG, Switzerland "Impact of Genetics and Genomics on Health Care: Opportunities and Challenges"
20:30	Welcome Reception
Friday, Sept 14, 2001
8:30-9:00	Registration
9:00-11:00	SESSION I Dr. Andreas Braun Chief Medical Officer, Sequenom Inc., USA "From SNPs to Medical Utility" Dr. Roger B Derbyshire Associate Director, Orchid BioSciences Europe Ltd, UK "Large Scale SNP Genotyping using Primer Extension on Multiple Platforms: Determination of Genome Wide SNP Allele Frequency Map" Mr. Stanford (Ford) N. Goldman, Jr. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., USA "Capital Formation: From Start-up to IPO, The American Experience"
11:00-11:20	Coffee/tea break
11:20-13:20	SESSION II Dr. Ian Dunham Sanger Centre, Hinxton, Cambridge, UK "The Human Genome Project" Dr. Wojciech Makalowski Department of Biology and Institute of Molecular Evolutionary Genetics, Pennsylvania State University, Pennsylvania, USA "Computational Genomics - Promises and Challenges" Dr. Olli-P. Kallioniemi National Human Genome Research Institute, National Institutes of Health, Bethesda, USA "Biochip Technologies in Cancer Research: From Genome Screening to Identification of Therapeutic Targets"
13:20-14:30	Lunch
14:30-15:40	SESSION III Dr. Mark S. Chee, Vice President of Genomics, Illumina Inc., USA "Accessing Genetic Information: Technology for Large Scale SNP Genotyping" Dr. Richard Grosse, CEO, InGene, Germany "PHENOME^TM: The Clinical Database for Phenotype Driven Genotyping"
15:40-16:00	Coffee/tea break
16:00-17:40	SESSION IV Prof. Andres Metspalu Department of Biotechnology, University of Tartu, Estonia "Estonian Genome Project: Current Status, Permissive Technologies and Future Steps" Dr. Kalev Kask Stanford University, USA "Estonian Genome Project: From Candidate Genes to Personalized Medicine" Prof. Gisli Palsson, Director and Professor, Institute of Anthropology, University of Iceland, Iceland "For Whom the Cells Toll: Debates About Biomedicine"
20:00	Buffet Dinner
Saturday, Sept 15, 2001
9:00-10:20	SESSION V Prof. Ralf Baumeister Genzentrum, Ludwig-Maximilians-Universität, Munich, Germany "C.elegans, an Animal Model for the Functional Analysis of Human Disease Genes" Prof. Charles Kurland University of Lund, Sweden "Vanishing Genomes, Emergent Proteomes: Evolving Mitochondria"
10:20-10:40	Coffee/tea break
10:40-12:00	SESSION VI Dr. Francois Cambien Institut National de la Sante et de la Recherche Medicale (INSERM), France "Genetics of Multifactorial Diseases" Prof. Stylianos E. Antonarakis Department of Medical Genetics, University of Geneva, Switzerland "Chromosome 21; a Small Genomic Land of Fascinating Disorders"
12:00-13:10	Lunch
13:10-14:30	SESSION VII Prof. Thomas Meitinger Institute of Human Genetics, Neuherberg, Germany "Complexity in Genetic Eye Disease" Dr. Massimo Carella, Telethon Institute of Genetics and Medicine (TIGEM), Napoli, Italy "The Genetics of Hearing Loss"
14:30-14:50	Coffee break
14:50-17:00	SESSION VIII Dr. Nick Short Chief Executive Officer, UVS Iceland Genomics Corporation, Iceland "Clinical Genomics and the Icelandic Cancer Project" Prof. Mart Ustav Department of Microbiology and Virology, University of Tartu, Estonia "Gene Therapy and Gene Vaccination" Dr. Priit Kogerman National Institute of Chemical Physics and Biophysics, Tallinn, Estonia. "From Genes to Functions: the Case of CD44" Prof. Giovanni Romeo Director, Unit of Genetic Susceptibility to Cancer, International Agency for Research on Cancer, Lyon, France "Genetics of Complex Diseases:the RET Protooncogene and Thyroid Cancer"
17:00	Closing remarks

Organisers reserve a right to make changes in the provisional programme as required.